OCT 5 - 6 2016
Cancer Research & Oncology
57 147 25364

The 4th Annual Cancer Research & Oncology Virtual Conference is now On Demand! This premier cancer research conference makes it easier and more cost-effective for the cancer research community to come together online to learn about recent advances in cancer research. The conference has proven to be a great success in disseminating knowledge and encouraging collaboration and connections between colleagues. View this conference at no charge, at any time!

Cancer Research & Oncology 2016 features informative presentations from keynote speakers and experts including; Dr. Giacinto Scoles, Dr. Gordon Freeman, Dr. Louise Perkins, Dr. David Albala, Dr. Judd Moul, And Dr. Raoul Concepcion.  Check out the virtual conference to view these and other great speakers at your convenience.

Watch this video to learn about this exciting conference!

Our virtual conference allows you to participate in a global setting with no travel or cost to you. You can participate in exactly those parts which you are interested in and be back at your desk or bench in an instant. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so. This virtual conference also offers increased reach for the global cancer community with a high degree of interaction through live-streaming video and chat sessions.

Topics for this year’s conference include:

  • Innovations in Cancer Immunotherapy
  • Targeted, Precision Cancer Therapies for Advanced Disease
  • Detection of Rare Cancer Mutations and Implications for Treatment
  • Novel Systems to Monitor Disease and Better Predict Clinical Outcomes for Cancer Patients
  • Mini-Symposiums on Prostate cancer, Breast cancer, Brain cancer, and the kRAS initiative

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (CE) and/or Continuing Medical Education (CME) credits. To earn educational credits, you must view an entire presentation. Following the presentation you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRcancer to follow the conversation
 


Speakers:
  • Donner Professor of Science and Professor of Chemistry, Emeritus
  • Professor of Medicine, Harvard Medical School
  • Chief of Urology at Crouse Hospital and Medical Director for Associated Medical Professionals
  • Director of Clinical Research of Urology Associates (UA)
  • Associate Director/Integrative Genomics and Group Leader, Genome Institute of Singapore
  • Professor, Public Health Research Institute, New Jersey Medical School, Rutgers University
  • James H Semans MD Professor of Surgery, Division of Urologic Surgery, , Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center
  • Chief Science Officer, Melanoma Research Alliance
  • Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, Associate Director, Toxicology Laboratory, University of Pennsylvania Perelman Scho
  • Target Biology Group Lead, National Cancer Institute
  • Principal Scientist, QIAGEN Bioinformatics
  • Senior Vice President of Research and Development, NanoString Technologies
  • Chief Medical Officer, NanoString Technologies
  • Chair of Biophysics and Professor, Ruhr-University Bochum, Department of Biophysics, Bochum, Germany
  • Director, Liquid Biopsy and Site Manager, QIAGEN Hannover Germany
  • Assistant Professor of Cancer Biology, Assistant Professor of Pathology, Microbiology, and Immunology, Vanderbilt University
  • Executive Director of Precision Medicine & Precision Genomics, Intermountain Healthcare
  • Manager, Field Applications Scientist, Personalis, Inc.
  • Global Product Manager at QIAGEN

Show Resources
Agenda
All times are Pacific Time
  • OCT 05, 2016 06:00 AM PDT
    Speaker: Louise Perkins, PhD
  • OCT 05, 2016 06:00 AM PDT
    Speaker: Samuel Rulli
  • OCT 05, 2016 07:30 AM PDT
    Speaker: Giacinto Scoles, PhD
  • OCT 05, 2016 09:00 AM PDT
    Keynote Speaker: Biomarkers, Risk Stratification; Newly diagnosed prosate cancer and markers for post radical prostetectomy
  • OCT 05, 2016 10:30 AM PDT
    Comparative genetic and transcriptome analyses of Hepatocellular Carcinoma and Endometrioid Endometrial Carcinoma highlight common molecular and biological processes
    Speaker: Jean-Noel Billaud, PhD
  • OCT 05, 2016 10:30 AM PDT
    Speaker: Michael Milone, PhD
  • OCT 05, 2016 10:30 AM PDT
    Joseph Beechem, PhD
    Senior Vice President of Research and Development, Nan...
    Alessandra Cesano, MD, PhD
    Chief Medical Officer, NanoString Technologies
  • OCT 05, 2016 12:00 PM PDT
    Speaker: Klaus Gerwert, PhD
  • OCT 05, 2016 12:00 PM PDT
    Speaker: Fred Kramer, PhD
  • OCT 06, 2016 06:00 AM PDT
    Speaker: Siegfried Hauch
  • OCT 06, 2016 06:00 AM PDT
    Speaker: Raoul Concepcion, MD
  • OCT 06, 2016 07:30 AM PDT
    Speaker: Shyam Prabhakar, PhD
  • OCT 06, 2016 09:00 AM PDT
    Speaker: Gordon Freeman, PhD
  • OCT 06, 2016 10:30 AM PDT
    Decoding human tumors and healthy tissue with mass cytometry
    Speaker: Jonathan Irish, PhD
  • OCT 06, 2016 10:30 AM PDT
    Speaker: Erin Newburn, MS, PhD
  • OCT 06, 2016 12:00 PM PDT
    Speaker: Lincoln Nadauld, MD, PhD
  • Therapeutics
  • OCT 05, 2016 06:00 AM PDT
    Speaker: Louise Perkins, PhD
  • OCT 05, 2016 10:30 AM PDT
    Speaker: Michael Milone, PhD
  • OCT 06, 2016 09:00 AM PDT
    Speaker: Gordon Freeman, PhD
  • Screening, Diagnosis, and Early Detection
  • OCT 05, 2016 06:00 AM PDT
    Speaker: Samuel Rulli
  • OCT 05, 2016 07:30 AM PDT
    Speaker: Giacinto Scoles, PhD
  • OCT 05, 2016 12:00 PM PDT
    Speaker: Fred Kramer, PhD
  • OCT 06, 2016 06:00 AM PDT
    Speaker: Siegfried Hauch
  • Imaging and Treatment
  • OCT 05, 2016 09:00 AM PDT
    Keynote Speaker: Biomarkers, Risk Stratification; Newly diagnosed prosate cancer and markers for post radical prostetectomy
  • OCT 06, 2016 10:30 AM PDT
    Speaker: Erin Newburn, MS, PhD
  • Cancer Biology
  • OCT 05, 2016 10:30 AM PDT
    Comparative genetic and transcriptome analyses of Hepatocellular Carcinoma and Endometrioid Endometrial Carcinoma highlight common molecular and biological processes
    Speaker: Jean-Noel Billaud, PhD
  • OCT 05, 2016 10:30 AM PDT
    Joseph Beechem, PhD
    Senior Vice President of Research and Development, Nan...
    Alessandra Cesano, MD, PhD
    Chief Medical Officer, NanoString Technologies
  • OCT 05, 2016 12:00 PM PDT
    Speaker: Klaus Gerwert, PhD
  • OCT 06, 2016 06:00 AM PDT
    Speaker: Raoul Concepcion, MD
  • OCT 06, 2016 07:30 AM PDT
    Speaker: Shyam Prabhakar, PhD
  • OCT 06, 2016 10:30 AM PDT
    Decoding human tumors and healthy tissue with mass cytometry
    Speaker: Jonathan Irish, PhD
  • OCT 06, 2016 12:00 PM PDT
    Speaker: Lincoln Nadauld, MD, PhD
Speakers

  • Giacinto Scoles, PhD
    Donner Professor of Science and Professor of Chemistry, Emeritus
    Biography
      Giacinto Scoles (b. 1935, married to Lim Giok Lan since 1964) is Donner professor of Science, Emeritus at Princeton University, distinguished adjoint professor in the Departments of Physics and Biology at Temple University, and distinguished scientist at Synchrotron Elettra in Trieste. He is presently senior grantee of the ERC in the faculty of Medicine at the University of Udine (Italy). His career has spanned an unusually long length of time and an equally unusually broad range of subjects. He has developed instrumentation in mass spectroscopy, gas viscosimetry, crossed molecular beam scattering, clusters formation and spectroscopy, surface monolayer, grazing incidence X-ray scattering, super-fluid helium droplets; manipulation of bio-molecules, bio-molecular interaction at the nano scale and medical nano diagnostics. He and a group of collaborators have recently patented a method to count circulating tumor cells based on the measurement of the metabolism of every cell isolated into a droplet of blood of several picoliters. When the droplet results to become acid, that indicates the presence of the cancer cells. He has received several recognitions: the Herschbach prize (2013); the gold medal of honor of the Italian Chemical Society; the Ben Franklin Medal for Physics (2006) 2 Honorary doctorates (1997 and 2000) the Debye prize of the ACS, the Plyler prize of the APS and the Lippincott Award of the OSA. He is a Fellow of the APS, OSA and of the ROYAL Society of the UK and of the Royal Science Academy of the Netherlands (KNAW). He has published about 300 papers in peer reviewed journals, and has been quoted by his colleagues approximately 19.000 times, his H-index is 73, while the i10-index is 224. He has supervised about a hundred PhD students, an unusually high percentage of which now covers positions of responsibility in Academia and research.
    • Gordon Freeman, PhD
      Professor of Medicine, Harvard Medical School
      Biography
        Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction. He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology for this work that led to development of PD-1 pathway blockade for cancer immunotherapy.
      • David Albala, MD
        Chief of Urology at Crouse Hospital and Medical Director for Associated Medical Professionals
        Biography
          Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to full Professor in Urology and Radiology in eight years. After 10 years, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 150 publications in peer-reviewed journals and has authored three textbooks in endourology and one in general urology. He serves on the editorial board for the Journal of Robotic Surgery, Journal of Endourology, Current Opinions in Urology and Urology Index and Reviews. He serves as a reviewer for eight surgical journals. At the present time he is Chief of Urology at Crouse Hospital in Syracuse, New York and Medical Director for Associated Medical Professionals. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 16 fellows in endourology and advanced robotic surgery. In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.
        • Raoul Concepcion, MD
          Director of Clinical Research of Urology Associates (UA)
          Biography
            Raoul S. Concepcion, M.D., F.A.C.S., is the current Director of Clinical Research of Urology Associates (UA), a fully integrated 32 physician Urology group in Nashville Tennessee. He is Immediate Past President of the Large Urology Group Practice Association (LUGPA), a non for profit entity representing the interests of over 2500 Urologists in the U.S. affiliated with large single specialty Urology groups. Dr. Concepcion was a General Surgery and Urology Resident at Vanderbilt University School of Medicine from 1984 - 1989. He served as Chief Urology Resident from 1989 - 1990 and was also a research fellow in the Light Laboratories at Vanderbilt. He has been in practice with Urology Associates since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction. He has an academic appointment at The Vanderbilt School of Medicine as Associate Clinical Professor, Department of Urology. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeon and the Nashville Surgical Society. He also serves as a board member for ZERO, a non for profit organization for prostate cancer research based in Washington D.C., and the Nashville chapter of Gilda's Club. Dr. Concepcion serves as a speaker or consultant for many pharmaceutical and laboratory companies in the advanced prostate cancer and biomarker world, including Amgen, Dendreon, Janssen, Medivation, Astellas, Bayer, Algeta, Takeda, Mitomics, Myriad, Metamark Genetics and MDxHealth. He is also the co-founder of CUSP, a urology specific clinical trials organization, and Medical Advisor to the Chan Soon-Shiong Institute for Advanced Health and NantHealth.
          • Shyam Prabhakar, PhD
            Associate Director/Integrative Genomics and Group Leader, Genome Institute of Singapore
            Biography
              Shyam Prabhakar obtained a B.Tech in Electronics and Communications Engineering from IIT-Madras and a PhD in Applied Physics from Stanford University. He was the sole recipient of the 2001 American Physical Society thesis award in Beam Physics. As a postdoctoral fellow under Eddy Rubin at the Lawrence Berkeley National Laboratory, he led seminal studies of human evolution through gene regulatory changes. In 2007 he joined the Genome Institute of Singapore, where his group uses single-cell RNA-seq, cohort-scale ChIP-seq and other high-throughput assays to uncover molecular mechanisms and diagnostic or prognostic markers of human diseases. In parallel, the group develops computational algorithms for deriving biological insights from functional genomics data.
            • Fred Kramer, PhD
              Professor, Public Health Research Institute, New Jersey Medical School, Rutgers University
              Biography
                Fred Russell Kramer is Professor of Microbiology and Molecular Genetics at the New Jersey Medical School, and has been a Principal Investigator at the Public Health Research Institute for the past 25 years. He graduated from the University of Michigan in 1964 and received his doctorate from the Rockefeller University in 1969. He was on the faculty of the Department of Genetics and Development at Columbia University College of Physicians and Surgeons for 17 years and has been a Research Professor and Adjunct Professor in the Department of Microbiology at New York University School of Medicine for the past 24 years.
              • Judd W Moul, MD, FACS
                James H Semans MD Professor of Surgery, Division of Urologic Surgery, , Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center
                Biography
                  Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland and an attending Urologic Oncologist at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. In addition, he was Director of the Center for Prostate Disease Research (CPDR); a Congress-mandated research program of the Department of Defense based at USUHS and WRAMC. In 2004, he completed a 26-year U.S. Army career, retiring as a full Colonel in the Medical Corps, and became Chief of the Division of Urologic Surgery at Duke. Serving as Chief from 2004 to 2011, he brought innovation and growth to the program. Most notably, he started the Duke Prostate Center, expanded the urology residency training program through a novel collaboration with the Department of Defense and was able to maintain Duke Urology as a top 10 program in the nation throughout his tenure. Dr Moul completed his Urologic Oncology Fellowship at Duke University and graduated Summa Cum Laude from Pennsylvania State University. He earned his medical degree from Jefferson Medical College, where he was elected to Phi Beta Kappa and Alpha Omega Alpha. Dr Moul currently serves on the editorial boards of Prostate Cancer, Prostate Cancer and Prostatic Diseases, BJU International, American Journal of Mens Health, Brazilian Journal of Urology, World Journal of Urology, and Oncology REALTIME. He has published over 500 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has appeared on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Associations Young Physicians Section Community Service Award for his national involvement in prostate cancer patient support groups, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the prestigious Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General at the US Army, and the Castle Connolly National Physician of the Year award.
                • Louise Perkins, PhD
                  Chief Science Officer, Melanoma Research Alliance
                  Biography
                    Dr. Perkins joined the Melanoma Research Alliance as Chief Science Officer in 2013 where she is responsible for the development and implementation of the MRA's scientific strategy including its research award program and annual Scientific Retreat. Her interests center on translational research including genomics, drug discovery and advancement of novel therapeutic approaches. She became a member of the Board of Directors of the Foundation for Sarcoidosis Research in late 2015. Prior to joining the MRA, she was Chief Scientific Officer at the Multiple Myeloma Research Foundation (MMRF) for five years, following a 16-year research career at two major pharmaceutical companies. While at the MMRF, Dr. Perkins led the expansion of its venture philanthropy activities including its Biotech Investment Award program and development of the scientific direction of its CoMMpasssm longitudinal study. Prior to joining the MMRF, Dr. Perkins was Director of Cancer Research at Bayer Pharmaceuticals, where she contributed to advancing novel targeted therapies toward clinical study including Nexavar® and other innovative signal transduction inhibitors. Prior to joining Bayer, she led a cancer research group at the Schering-Plough Research Institute participating in early-stage programs, including novel target-finding using human genomics data. Dr. Perkins graduated from the University of Michigan with a PhD and MS in Biological Chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology. She earned her BS in Zoology from the University of North Carolina at Chapel Hill.
                  • Michael Milone, PhD
                    Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, Associate Director, Toxicology Laboratory, University of Pennsylvania Perelman Scho
                    Biography
                      Dr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from Rutgers-New Jersey Medical School (formerly the University of Medicine and Dentistry of New Jersey). After an Internship in Internal Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training in Clinical Pathology, Transfusion Medicine and Laboratory Toxicology. Following clinical training, Dr. Milone pursued post-doctoral research training in cancer immunology and adoptive immunotherapy with Dr. Carl June at the University of Pennsylvania where he performed basic research to develop CTL019, a genetically modified T cell therapy for B-cell leukemia and lymphoma that has been licensed by Novartis and undergoing early phase clinical testing. He is currently an Assistant Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. At present, Dr. Milone's laboratory is focused on T cell biology and the development of new techniques for culturing and genetically modifying T lymphocytes for adoptive immunotherapy of cancer.
                    • Rachel Bagni, PhD
                      Target Biology Group Lead, National Cancer Institute
                    • Jean-Noel Billaud, PhD
                      Principal Scientist, QIAGEN Bioinformatics
                      Biography
                        Jean-Noel Billaud, Ph.D. is Principal Scientist at QIAGEN Bioinformatics. He joined Ingenuity Systems (now QIAGEN) in 2008 as staff scientist for in silico research program in oncology and infectious diseases. Jean-Noel Billaud holds a Ph.D. in Blood Cell Biology from Paris VII, and has done his post-doctoral work at the Scripps Research Institute (San Diego, CA).
                      • Joseph Beechem, PhD
                        Senior Vice President of Research and Development, NanoString Technologies
                        Biography
                          Since April 2012, Joe Beechem has led NanoString Technologies in its pursuit of next-generation immune-oncology. With deep expertise in genetic analysis, sequencing, and research, Dr. Beechem has directed the design and development of multiple genetic analysis technologies including various sequencing platforms.
                        • Alessandra Cesano, MD, PhD
                          Chief Medical Officer, NanoString Technologies
                          Biography
                            Alessandra Cesano is a leading expert in the field of immune-oncology. With more than 20 years of experience in R&D, management, and tumor immunology, she plays a key role in providing the overall clinical vision for NanoString Technologies as the organization continues to ignite new discoveries in cancer research.
                          • Klaus Gerwert, PhD
                            Chair of Biophysics and Professor, Ruhr-University Bochum, Department of Biophysics, Bochum, Germany
                            Biography
                              Klaus Gerwert studied physics in Münster and received his doctorate in 1985 in biophysical chemistry in Freiburg. After positions at the Max Planck Institute of Molecular Physiology in Dortmund and the Scripps Research Institute in La Jolla, USA, he accepted a university professorship in biophysics at Ruhr University Bochum in 1993. He is Fellow of the Max Planck Society since 2008, has been Director at the Max Planck Partner Institute for Computational Biology (PICB) at Shanghai, China, from 2008 to 2013. Gerwert actively promotes the development and application of vibrational spectroscopy in protein research, and is the holder of several patents. He is internationally recognized for his studies on protein structures, functions, and interactions at different scales: in vitro, at membranes and in vivo. Molecular biology, X-ray structure analysis, optical spectroscopy, in particular vibrational spectroscopy as infrared (IR) and Raman, are all well established in the department. In 2010, he founded the European "Protein Research Unit Ruhr within Europe" (PURE) with clinician colleagues. He is the founding director of ProDi, a federal/state-financed research center for molecular protein diagnostics including label-free FTIR imaging techniques applications in clinical research.
                            • Siegfried Hauch
                              Director, Liquid Biopsy and Site Manager, QIAGEN Hannover Germany
                              Biography
                                Dr. Siegfried Hauch studied biology at the Albert Einstein University in Ulm and received his PhD 1997 in plant physiology and molecular biology at the Eberhard Karls University Tübingen. Until 2001 he was Product Manager for imaging systems and microarray technologies at Biozym Diagnostics GmbH and changed therafter to AdnaGen AG as Marketing Manager in 2001. In addition to his marketing responsibilities he was director of R&D since 2006 to build, secure and enhance the AdnaGen circulating tumor cell business and, after the accquistion by Alere Inc. in 2010, he was holding the position as CSO and General Manager at Alere/AdnaGen GmbH. Since 2015 Dr. Hauch serves as Director of Liquid Biopsy and Site Manager at QIAGEN Hannover GmbH.
                              • Jonathan Irish, PhD
                                Assistant Professor of Cancer Biology, Assistant Professor of Pathology, Microbiology, and Immunology, Vanderbilt University
                                Biography
                                  Jonathan Irish is an assistant professor at Vanderbilt University in the departments of both Cancer Biology and of Pathology, Microbiology and Immunology. He holds BS degrees from the University of Michigan in biology, chemistry and biochemistry as well as a PhD in cancer biology from Stanford University. Before coming to Vanderbilt in December 2011, he trained at Stanford University with Garry Nolan (as a PhD student) and Ronald Levy (as a postdoc and instructor). There he created a new approach that measures signaling in individual cancer cells and applied it to the study of acute myelogenous leukemia (AML) patient clinical outcomes. He later applied this technique to healthy B cells and malignant B cells in follicular lymphoma (FL). In FL, signaling identified a subset of tumor B cells that were present at diagnosis only in patients with a lower overall survival (p <0.0001) and that increased over time as the patient's cancer progressed. Systems biology tools like Cytobank, a cloud computing platform he helped create to manage and analyze single-cell signaling data, were critical to this work. His experimental approach has focused on measuring signaling events in individual cells from primary tissues, including human tumors. A central goal of his research at Vanderbilt is to understand how changes at the single-cell level alter signaling in healthy cells and lead to therapy-resistant populations in human diseases.
                                • Lincoln Nadauld, MD, PhD
                                  Executive Director of Precision Medicine & Precision Genomics, Intermountain Healthcare
                                  Biography
                                    Dr. Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare, an integrated healthcare system located in the Intermountain West. Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he is still part of the research faculty focusing on cancer genomics and personalized cancer medicine. Dr. Nadauld oversees the clinical implementation of genomics cancer medicine across Intermountain Healthcare's 22 hospitals and 180 physician clinics. In his spare time Dr. Nadauld enjoys attending his children's sporting events, water sports, fishing and athletics.
                                  • Erin Newburn, MS, PhD
                                    Manager, Field Applications Scientist, Personalis, Inc.
                                    Biography
                                      Erin Newburn, MS, PhD, joined Personalis as a Field Application Scientist in 2013 with over 12 years of research experience in the areas of molecular biology, genetics, and biotechnology. As the Field Applications Manager, Erin's team has the responsibility for providing both pre and post-sale technical support for the Personalis ACE Cancer Portfolio. She completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Erin received her Ph.D. from the Ohio State University in Integrated Biomedical Science as a Presidential Fellow.
                                    • Samuel Rulli
                                      Global Product Manager at QIAGEN
                                      Biography
                                        Dr Samuel Rulli received his PhD in 2002 from Tulane University and pursued post-doctoral research at Johns Hopkins University and the National Cancer Institute in Frederick, MD. Trained as a molecular biologist, Dr. Rulli started working in industry in 2007 and has worked on different assay detection technologies for gene expression and nucleic acid analysis. Currently he is a global product manager at QIAGEN specializing in qPCR & NGS based detection of both protein and non-coding RNAs by pathway and disease.
                                      Sponsored By

                                      For information on becoming a sponsor or exhibitor, please click here.


                                      Continuing Education (CME/CE/CEU) Credits

                                      The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here

                                      The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here.

                                      The presentational method for this activity will be Lecture followed by Q&A. This virtual event targets all oncologists and primary care clinicians and is open to all health care professionals and academia. This activity will encompass the following desirable physician attributes: Patient Care & Procedural Skills, Medical Knowledge, Professionalism, and Practice-Based Learning & Improvement.
                                       
                                      Desired Outcomes - at the conclusion of the activity, participants should be able to:
                                      1. Integrate the provided content into practive in ways that are consistent with acknowledged practive guidelines and that improve patient management and outcomes
                                      2.Utilize technologies currently available for use in the clinic and the limitations of these technologies
                                      3.Apply current and established medical science principles and the application of these principles to patient care
                                      4.Practice continuous self-assessment and learning to improve one’s professional and clinical practices, including how to interpret results in ways most useful to the patient
                                      5.Cite the role of precision medicine in cancer research & oncology

                                       
                                      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of CME Consultants and LabRoots. CME Consultants is accredited by the IMQ/CMA to provide continuing medical education for physicians.
                                       
                                      CME Consultants designates this live activity for a maximum of 5.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
                                       


                                      Committee

                                      To download the Program Committee brochure here.


                                      • David Albala, MD

                                        Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                                        See more See less
                                      • R. Claudio Aguilar, Ph.D.

                                        Dr. Aguilar obtained his PhD degree in Immunochemistry from the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. Dr. Aguilar pursued his post-doctoral training at the National institutes of Health in Bethesda, MD in the lab of the well-known cell ...

                                        See more See less
                                      • Antonio Baines, PhD

                                        Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                        See more See less
                                      • Josip Blonder, MD

                                        Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI). In 1978, Dr. Blonder received his M.D. at the Rijeka University ...

                                        See more See less
                                      • Rajan Gupta, MD

                                        Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                                        See more See less
                                      • Eric Klein, MD

                                        Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate, testis and kidney. For several years, including the current edition, Dr ...

                                        See more See less
                                      • Fred Russell Kramer, PhD

                                        Fred Russell Kramer is Professor of Microbiology and Molecular Genetics at the New Jersey Medical School, and has been a Principal Investigator at the Public Health Research Institute for the past 25 years. He graduated from the University of Michigan in 1964 and received his ...

                                        See more See less
                                      • Martin Latterich, PhD

                                        The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                        See more See less
                                      • Ariel Louwrier PhD

                                        Successful Senior Scientific Business Executive with demonstrated expertise growing markets, revenues, product pipelines and expanding technical organizations into new business opportunities. Educational and business management experience in global markets, with quantified ...

                                        See more See less
                                      • Judd Moul, MD, FACS

                                        Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of ...

                                        See more See less
                                      • Thomas Polascik, MD

                                        Thomas J. Polascik, M.D. is Professor in the Duke Cancer Institute, the Department of Surgery at the Duke University Medical Center, Durham, NC. Dr. Polascik trained at the Brady Urological Institute, the Johns Hopkins Hospital in Baltimore Maryland. After finishing his residency ...

                                        See more See less
                                      Help

                                      General LabRoots Questions

                                      For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                      Contact us

                                      Virtual Events and Webinars

                                      Supported Configurations

                                      • Operating System Internet Explorer Firefox Chrome Safari
                                        Vista IE8+ FF10+ Chrome15+
                                        Windows 7 IE8+ FF10+ Chrome15+
                                        Windows 8 IE10 FF10+ Chrome15+
                                        Mac OS X   FF10+ Chrome15+ Safari5.1+
                                      • Cookie settings: session cookies enabled
                                      • Browser configuration must have JavaScript enabled
                                      • Adobe Flash player 10.2 or later

                                      To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                      Internet Connection

                                      • A minimum of 100Kbps is recommended for audio-only events
                                      • A minimum of 300Kbps is recommended for speaker on-video events

                                      Computer Equipment

                                      • Screen Resolution: Minimum 1024x768
                                      • Video Card: 65,000 colors minimum
                                      • Sound card and speakers (or headphones) for hearing webcast in full format
                                      • Audio Card: 16-bit minimum
                                      • RAM: 512MB of free RAM

                                      Firewall Protocol

                                      • HTTP on port 80 or HTTPS on port 443
                                      • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                      • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                      Work-At-Home Attendees

                                      • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                      For A Seamless Experience

                                      When using a mobile device, FREE Mobile Apps are available:

                                      - For viewing Webinars:

                                      - For viewing Virtual Events

                                      Attendee Guide

                                      • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                      Virtual Event and Webinar Support:

                                      Continuing Education (CME/CE) Support

                                      Loading Comments...
                                      Show Resources